231 filings
Page 3 of 12
DEFA14A
sx4qo3r6qifh
6 Aug 21
Additional proxy soliciting materials
4:16pm
8-K
8o0 d9il78qitth1e
9 Jun 21
Sio Gene Therapies Announces Fiscal Year 2020 Year-End Financial Results and Expected Fiscal Year 2021 Key Milestones
7:02am
8-K
1mdshmgoa7o7mr9y0
13 May 21
Sio Gene Therapies Announces CSF Reductions in GM1 Ganglioside from Clinical Trial of AXO-AAV-GM1 Gene Therapy
7:01am
8-K
u1oxasey
5 Apr 21
Departure of Directors or Certain Officers
5:10pm
8-K
molluk42k4y 9w
15 Mar 21
Sio Gene Therapies Provides Update on Cash Position and Major Upcoming GM1 Gangliosidosis Program Milestones
7:02am
8-K
tuxb0bq
9 Feb 21
Results of Operations and Financial Condition
7:02am
8-K
pfqk9yf0aumu3vc6c
4 Feb 21
Sio Gene Therapies Announces Receipt of $11.6 Million from Closing of the Sale of Arvelle Therapeutics
7:02am
8-K
r7xiz5s 3ne4s
3 Feb 21
Regulation FD Disclosure
7:03am
8-K
q4lw pejk9pv
4 Jan 21
Sio Gene Therapies to sell Arvelle Stake as part of Angelini Pharma’s Acquisition of Arvelle Therapeutics
8:01am
8-K
tl485x59d90
18 Dec 20
Entry into a Material Definitive Agreement
6:00am
424B5
oz04as1 jz61i
16 Dec 20
Prospectus supplement for primary offering
6:59am
8-K
d5m6h
15 Dec 20
Sio Gene Therapies Announces Positive Six-Month Follow-Up Data from Low-Dose Cohort of Phase 1/2 Trial of AXO-AAV-GM1 for GM1 Gangliosidosis
4:04pm
EFFECT
stkvlfw
20 Nov 20
Notice of effectiveness
12:15am
EFFECT
xf9qcegw0yysd53n vb1
20 Nov 20
Notice of effectiveness
12:15am
S-8 POS
fhx b0aqse
13 Nov 20
Registration of securities for employees (post-effective amendment)
5:27pm
POS AM
h02acw1lrryl83uv912
13 Nov 20
Prospectus update (post-effective amendment)
5:05pm